Pseudomonas Aeruginosa Infections Treatment Market - Competitive Landscape & Growth Opportunities 2024
Pseudomonas aeruginosa, a rod-shaped bacterium, is usually found in moist or wet areas such as water and soil. Pseudomonas aeruginosa infection is the most common type of Pseudomonas infections and is caused by strain of bacteria abundantly found in the environment. This bacterial strain usually do not cause harm in healthy people but are ‘opportunistic’ pathogens to cause infection in patients with compromised immune function. Therefore, the main threat is posed to most vulnerable subjects such as hospitalized patients, particularly those in intensive care units, and cancer patients, people with severe burns, and babies in the neonatal units. Pseudomonas aeruginosa is listed as one of the six most dangerous drug-resistant microbes and more than 15% of P. aeruginosa isolates were found resistant to at least three classes of antibiotics which signifies the huge treatment gap present today.
Pseudomonas Aeruginosa Infections can involve several parts of body and the severity and type of illness depends on its entry route and site into the body. Various sites where this infection can cause harm are respiratory tract, blood stream, gastrointestinal tract, urinary tract, cardiovascular system, nervous system, ear, eye, bones and joints, and skin. Pseudomonal infections often become complicated to mange and can be life-threatening. Pseudomonas infections are usually treated with antibiotics. However, antibiotic resistance for these infections is increasing which makes more difficult to treat. The economic burden of healthcare associated infection (HAIs) is very high which have increased the demand for solutions that can be helpful in reducing these infections and the costs associated with them.
Browse Full Report With ToC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=17156
Global Pseudomonas Aeruginosa Infections Treatment Market: Trends and Opportunities
Multi-drug resistant (MDR) Pseudomonas poses life threatening danger to patients in critical care. In the U.S. more than 51,000 P. aeruginosa infections occur annually which are associated with healthcare settings such as nursing homes and hospitals. Out of these more than 13% are multidrug-resistant (MDR) phenotype. These multidrug resistance Pseudomonas infections have been highlighted with serious level of threat in a report ‘Antibiotic resistance threats in the United States, 2013’ presented by the Centers for Disease Control and Prevention (CDC). This eventually presents a market opportunity for the companies which can provide solutions in terms of diagnostics, treatment and prevention of Pseudomonas aeruginosa infections. The market for Pseudomonas aeruginosa infections treatment is driven by rate of mortality and lack of drugs which can combat MDR phenotypes of P. aeruginosa. Several pharmaceutical companies are striving to bring innovative drugs into market which can treat Pseudomonas infections.
The large companies such as Roche has been trying to capitalize the unmet market needs through collaboration and licensing agreements. For instance, Roche entered into an exclusive worldwide agreement with Polyphor Ltd., to develop and commercialize latter company’s investigational antibiotic, POL7080. The companies in the market have historically focused in the United States and Europe. However, with the increasing competition in these geographies, the larger players are encouraged to engage in untapped markets in Asia and Latin America.
Fill the form for an exclusive sample of this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17156
Global Pseudomonas Aeruginosa Infections Treatment Market: Key Players
Some of the companies in the global Pseudomonas aeruginosa infections treatment market include Achaogen, Inc., AmpliPhi Biosciences Corporation, Aridis Pharmaceuticals LLC, Cantab Biopharmaceuticals Ltd., FOB Synthesis, Inc., Forest Laboratories, Inc., GlycoVaxyn AG, Insmed, Inc., KaloBios Pharmaceuticals, Inc., Lytix Biopharma AS, Melinta Therapeutics, Inc., Microbiotix, Inc., Novabiotics Ltd., Omnia Molecular Ltd., PARI Pharma GmbH, Pfizer, Inc., Pherecydes Pharma SA., Phico Therapeutics Ltd., Polyphor Ltd., Procarta Biosystems Ltd., Sequoia Sciences, Inc., Soligenix, Inc., Tetraphase Pharmaceuticals, Inc., Therametrics Holding AG, and Trana Discovery, Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.
We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Transparency Market Research
90 State Street, Suite 700, Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
Visit Blog: http://marketresearchreports2017.blogspot.in
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pseudomonas Aeruginosa Infections Treatment Market - Competitive Landscape & Growth Opportunities 2024 here
News-ID: 726550 • Views: 341
More Releases from Transparency Market Research - Pharmaceutical
Neurovascular Devices Market Business Opportunities and Growth Challenges Report
Global Neurovascular Devices Market: Overview The global population is aging rapidly. According to WHO, the chances of health risks are greater in geriatric people than the young generation. Old age is considered to be one of the biggest risk factors that are responsible for developing various diseases such as cardiovascular and neurological conditions. It is because of these factors, the global neurovascular devices market is experiencing robust growth in the
Pneumococcal Vaccines Market anticipated expand at a CAGR of 3.3% from 2018 to 2 …
Transparency Market Research (TMR) has published a new report titled, “Pneumococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global pneumococcal vaccines market was valued at US$ 7,247.6 Mn in 2017 and is anticipated expand at a CAGR of 3.3% from 2018 to 2026. Increase in patient pool, growth of the pharmaceutical industry, government initiatives to increase vaccination programs, rise
Swab and Viral Transport Medium Market projected to expand at a CAGR of ~3% from …
Swab and Viral Transport Medium Market: Introduction Transparency Market Research has published a new report titled, ‘Global Swab and Viral Transport Medium Market ’. According to the report, the global swab and viral transport medium market was valued at US$ 0.9 Bn in 2019 and is projected to expand at a CAGR of ~3% from 2020 to 2030. Viral transport medium (VTM) enables safe transfer of viruses, chlamydia, and mycoplasma for
Radiofrequency Ablation Devices Market by Product, Geography and Forecast to 202 …
Transparency Market Research (TMR) has published a new report titled, 'Radiofrequency Ablation Devices for Pain Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027'. According to the report, the global radiofrequency ablation devices for pain management market was valued at US$ 543.0 Mn in 2018 and is projected to expand at a CAGR of above 11.0% from 2019 to 2027. Overview Radiofrequency ablation is a minimally invasive surgical
More Releases for Pseudomonas
Pseudomonas aeruginosa Infections-Pipeline Review H2 2018
ReportsWeb latest Pharmaceutical and Healthcare disease pipeline guide Pseudomonas aeruginosa Infections-Pipeline Review, H2 2018, provides an overview of the Pseudomonas aeruginosa Infections (Infectious Disease) pipeline landscape. Pseudomonas aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It has an ability to rapidly develop resistance to multiple classes of antibiotics. It is the most common pathogen isolated from patients who have been hospitalized for more
Pseudomonas Diagnostic Testing Market Significantly Expand over 2021
Pseudomonas is a group of gram-negative, rod-shaped bacteria, commonly found in soil, plants, groundwater, and animals. Pseudomonas aeruginosa is a common bacterium belonging to the Pseudomonas family. This bacterium is found on the surface of plants and animals. Infections caused by pseudomonas bacteria are termed as pseudomonas infections. Healthy people are usually not at risk of contracting such type of infections. However, people with a weakened immune system, especially due
Resistant Pseudomonas aeruginosa Infections Pipeline Review, H2 2017
"The Report Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2017, provides an overview of the Resistant Pseudomonas aeruginosa Infections (Infectious Disease) pipeline landscape. Pseudomonas aeruginosa has become an important cause of infection, especially in patients
Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H1 2017, provides an overview of the Resistant Pseudomonas aeruginosa Infections (Infectious Disease) pipeline landscape. Pseudomonas aeruginosa has become an important cause of infection, especially in patients
Pipeline Review of Pseudomonas Aeruginosa Pneumonia and Market Report 2017
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Pseudomonas aeruginosa Pneumonia - Pipeline Review, H1 2017” to its report offerings. The report provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of
Global Pseudomonas Diagnostic Testing Market
The Pseudomonas Diagnostic Testing Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Pseudomonas is a group of gram-negative, rod-shaped bacteria, commonly found in soil, plants, groundwater, and animals. Pseudomonas aeruginosa is a common bacterium belonging to the Pseudomonas family. This bacterium is